$ZTS

$ZTS - Zoetis (ZTS) reported Q1 2026 revenue of $2.3 billion (up 3% reported, flat organic) and adjusted EPS of $1.53 (up 9% reported, 7% organic), while revising full-year 2026 revenue guidance to $9.680–$9.960 billion (2–5% organic growth) and adjusted EPS to $6.85–$7.00, citing a challenging environment with pet owner price sensitivity, declining vet visits, and intensified competition in dermatology.